199 related articles for article (PubMed ID: 30775983)
1. Distinctive Neurochemistry in Alzheimer's Disease via 7 T In Vivo Magnetic Resonance Spectroscopy.
Marjańska M; McCarten JR; Hodges JS; Hemmy LS; Terpstra M
J Alzheimers Dis; 2019; 68(2):559-569. PubMed ID: 30775983
[TBL] [Abstract][Full Text] [Related]
2. Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.
Waragai M; Moriya M; Nojo T
J Alzheimers Dis; 2017; 60(4):1411-1427. PubMed ID: 28968236
[TBL] [Abstract][Full Text] [Related]
3. Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using
Marjańska M; McCarten JR; Hodges J; Hemmy LS; Grant A; Deelchand DK; Terpstra M
Neuroscience; 2017 Jun; 354():168-177. PubMed ID: 28476320
[TBL] [Abstract][Full Text] [Related]
4. Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study.
Schott JM; Frost C; MacManus DG; Ibrahim F; Waldman AD; Fox NC
Brain; 2010 Nov; 133(11):3315-22. PubMed ID: 20739347
[TBL] [Abstract][Full Text] [Related]
5. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
Jones RS; Waldman AD
Neurol Res; 2004 Jul; 26(5):488-95. PubMed ID: 15265265
[TBL] [Abstract][Full Text] [Related]
6. Predicting conversion from mild cognitive impairment to Alzheimer's disease using brain
Mitolo M; Stanzani-Maserati M; Capellari S; Testa C; Rucci P; Poda R; Oppi F; Gallassi R; Sambati L; Rizzo G; Parchi P; Evangelisti S; Talozzi L; Tonon C; Lodi R; Liguori R
Neuroimage Clin; 2019; 23():101843. PubMed ID: 31071594
[TBL] [Abstract][Full Text] [Related]
7. Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment.
Foy CM; Daly EM; Glover A; O'Gorman R; Simmons A; Murphy DG; Lovestone S
Brain Topogr; 2011 Oct; 24(3-4):316-22. PubMed ID: 21298332
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
9. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
[TBL] [Abstract][Full Text] [Related]
10. Diffusion tensor imaging correlates with proton magnetic resonance spectroscopy in posterior cingulate region of patients with Alzheimer's disease.
Ding B; Chen KM; Ling HW; Zhang H; Chai WM; Li X; Wang T
Dement Geriatr Cogn Disord; 2008; 25(3):218-25. PubMed ID: 18219201
[TBL] [Abstract][Full Text] [Related]
11. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
Huang W; Alexander GE; Chang L; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
Neurology; 2001 Aug; 57(4):626-32. PubMed ID: 11524470
[TBL] [Abstract][Full Text] [Related]
12. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.
Huang W; Alexander GE; Daly EM; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
Am J Psychiatry; 1999 Dec; 156(12):1879-86. PubMed ID: 10588400
[TBL] [Abstract][Full Text] [Related]
13. Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.
Wang T; Xiao S; Li X; Ding B; Ling H; Chen K; Fang Y
Int Psychogeriatr; 2012 Jan; 24(1):19-27. PubMed ID: 21676281
[TBL] [Abstract][Full Text] [Related]
14. Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T.
Antuono PG; Jones JL; Wang Y; Li SJ
Neurology; 2001 Mar; 56(6):737-42. PubMed ID: 11274307
[TBL] [Abstract][Full Text] [Related]
15. An 1H-MRS framework predicts the onset of Alzheimer's disease symptoms in PSEN1 mutation carriers.
Londono AC; Castellanos FX; Arbelaez A; Ruiz A; Aguirre-Acevedo DC; Richardson AM; Easteal S; Lidbury BA; Arcos-Burgos M; Lopera F
Alzheimers Dement; 2014 Sep; 10(5):552-61. PubMed ID: 24239247
[TBL] [Abstract][Full Text] [Related]
16. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Modrego PJ; Pina MA; Fayed N; Díaz M
CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
[TBL] [Abstract][Full Text] [Related]
17. [Hydrogen proton MR spectroscopy of posterior portion cingulate gyrus of patients with Alzheimer's disease: a case control study].
Wang T; Xiao SF; Li X; Wang Y; Ding B; Ling HW; Chen KM
Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(1):37-40. PubMed ID: 19489242
[TBL] [Abstract][Full Text] [Related]
18. Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer's disease.
Watanabe T; Shiino A; Akiguchi I
Neurobiol Learn Mem; 2012 Mar; 97(3):289-93. PubMed ID: 22390859
[TBL] [Abstract][Full Text] [Related]
19. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
20. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Waldman AD; Rai GS
Neuroradiology; 2003 Aug; 45(8):507-12. PubMed ID: 12879326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
